RxDoctor Payments Data

Michelle Abis, MD

Internal Medicine · Rhinebeck, NYNPI 1437144359

Payments from drug & device makers

$1,090in general payments, 2019–2025

Across 58 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$340
  • AstraZeneca$177
  • Pfizer$165
  • Novo Nordisk$131
  • Lilly USA, LLC$98
  • Johnson & Johnson$60
  • plus $119 from 4 others

What the payments were for

  • Food & beverage$1,090100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,090 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$141,291
Medicare patients
364
Services billed
1,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban159$147,066
OzempicSemaglutide113$144,232
MounjaroTirzepatide69$87,879
Trelegy ElliptaFluticasone/Umeclidin/Vilanter86$70,171
JardianceEmpagliflozin56$56,220
FarxigaDapagliflozin Propanediol44$38,812
ProliaDenosumab17$28,608
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$22,328
TrulicityDulaglutide14$20,267
Breo ElliptaFluticasone/Vilanterol34$17,989
XareltoRivaroxaban20$17,586
OxycontinOxycodone Hcl21$15,492
Incruse ElliptaUmeclidinium Bromide32$14,134
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$9,790
EntrestoSacubitril/Valsartan12$8,550

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$165$147,066159 claims
Novo NordiskOzempic$131$144,232113 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$19$124,623199 claims
Lilly USA, LLCMounjaro, Trulicity$98$108,14683 claims
AstraZenecaFarxiga$177$38,81244 claims
Johnson & JohnsonXarelto$60$17,58620 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$5,104456 claims
Kowa Pharmaceuticals America, Inc.Livalo$29$4,79411 claims
AbbVieSynthroid$340$4,22662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rhinebeck

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →